Cost analysis of HIV treatment and drug-related adverse events when fixed-dose combinations of antiretrovirals (FDCs) were stopped, versus continuation with FDCs

Francesc Homar (), Virginia Lozano (), Juan Martínez-Gómez (), Itziar Oyagüez (), Antonio Pareja (), Antoni Payeras (), Joaquín Serrano (), Carmen Carratalá () and Miguel Casado ()

Health Economics Review, 2012, vol. 2, issue 1, 1-9

Abstract: Our study suggests that the discontinuation of FDC treatment and the replacement with the administration of separate antiretroviral agents could lead to an increase in healthcare costs due to the higher rate of adverse events that was observed with the discontinuation of FDCs. Copyright Homar et al.; licensee Springer. 2012

Keywords: HIV; Fixed-dose combination; Antiretrovirals; Cost-analysis; Spain (search for similar items in EconPapers)
Date: 2012
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://hdl.handle.net/10.1186/2191-1991-2-16 (text/html)
Access to full text is restricted to subscribers.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:hecrev:v:2:y:2012:i:1:p:1-9:10.1186/2191-1991-2-16

Ordering information: This journal article can be ordered from
http://www.springer.com/journal/13561

DOI: 10.1186/2191-1991-2-16

Access Statistics for this article

Health Economics Review is currently edited by J. Matthias Graf von der Schulenburg

More articles in Health Economics Review from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().